Antidepressant monoamine oxidase inhibitors enhance serotonin but not norepinephrine neurotransmission.

作者: P. Blier , C. Montigny

DOI: 10.1007/978-3-642-71288-3_15

关键词:

摘要: Monoamine oxidase inhibitors (MAOIs) were the first effective drugs in treatment of major depression (Klein et al. 1980). Given their inhibiting action on catabolism monoaminergic neurotransmitters, they constitute unique tools for investigating neurobiological basis antidepressant response.

参考文章(28)
Aghajanian Gk, Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. Essays in neurochemistry and neuropharmacology. ,vol. 3, pp. 1- 32 ,(1978)
A J Frances, R D Brown, S F Aarons, J J Mann, Studies of selective and reversible monoamine oxidase inhibitors. The Journal of Clinical Psychiatry. ,vol. 45, pp. 62- 66 ,(1984)
Moussa B. H. Youdim, Essays in neurochemistry and neuropharmacology Wiley. ,(1977)
S Z Langer, Presynaptic regulation of the release of catecholamines. Pharmacological Reviews. ,vol. 32, pp. 337- 362 ,(1980)
N. H. Neff, H.-Y. T. Yang, THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES Journal of Pharmacology and Experimental Therapeutics. ,vol. 189, pp. 733- 740 ,(1974)
J.P. Johnston, Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology. ,vol. 17, pp. 1285- 1297 ,(1968) , 10.1016/0006-2952(68)90066-X
J. Craig Nelson, Robert Byck, Rapid response to lithium in phenelzine non-responders. British Journal of Psychiatry. ,vol. 141, pp. 85- 86 ,(1982) , 10.1192/BJP.141.1.85